Hall Approved Free Access to American Case Law

Classen Immunotherapies, Inc. v. Biogen Idec

U.S. Court of Appeals for the Federal Circuit
Classen Immunotherapies, Inc. v. Biogen Idec, 304 F. App'x 866 (Fed. Cir. 2008)
Moore

Classen Immunotherapies, Inc. v. Biogen Idec

Opinion of the Court

MOORE, Circuit Judge.

In light of our decision in In re Bilski, 545 F.3d 943 (Fed.Cir. 2008) (en banc), we affirm the district court’s grant of summary judgment that these claims are invalid under 35 U.S.C. § 101. Dr. Classen’s claims are neither “tied to a particular machine or apparatus” nor do they “transforme ] a particular article into a different state or thing.” Bilski, 545 F.3d at 954. Therefore we affirm.

Reference

Full Case Name
CLASSEN IMMUNOTHERAPIES, INC. v. BIOGEN IDEC, and GlaxoSmithKline, and Merck & Co., Inc., Defendant-Cross and Chiron Corporation, Kaiser-Permanente, Inc., Kaiser Permanente Ventures, Kaiser Permanente International, Kaiser Permanente Insurance Company, The Permanente Federation, LLC, The Permanente Company, LLC, The Permanente Foundation, The Permanente Medical Group, Inc., Kaiser Foundation Hospitals, Kaiser Foundation Added Choice Health Plan, Inc., And Kaiser Foundation Health Plan Inc.
Cited By
3 cases
Status
Published
↑